AVIR

MKT CAP:$435M

Atea Pharmaceuticals, Inc.

Market Cap

$435M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$5.71+$2.23 (+64.08%)

Apr 20, 2026

Company Details

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an an...

CEO

Jean-Pierre Sommadossi

IPO Date

Oct 30, 2020

Website

ateapharma.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$158M

EPS (Diluted)

-$1.94

Free Cash Flow

-$132M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 11, 2026

PENDING

FY 2025

Mar 5, 2026

$0EPS -$1.94

Q4 2025

Mar 5, 2026

$0EPS -$0.57

Q3 2025

Nov 12, 2025

$0EPS -$0.53

Q2 2025

Aug 7, 2025

$0EPS -$0.44

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	-$30M	-$42M
Q2 22	$0	$0	-$32M
Q3 22	$0	$0	-$16M
Q4 22	$0	-$15M	-$40M
Q1 23	$0	-$29M	-$42M
Q2 23	$0	-$16M	-$35M
Q3 23	$0	-$18M	-$41M
Q4 23	$0	-$104.0K	-$47M
Q1 24	$0	-$104.0K	-$70M
Q2 24	$0	-$104.0K	-$47M
Q3 24	$0	-$20M	-$37M
Q4 24	$0	-$104.0K	-$39M
Q1 25	$0	-$3M	-$39M
Q2 25	$0	-$2M	-$41M
Q3 25	$0	$0	-$46M
Q4 25	$0	-$104.0K	-$55M

Valuation

Quarter	P/S	P/E
Q1 22	2.0x	12.0x
Q2 22	2.6x	38.2x
Q3 22	2.5x	13.5x
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	—	—
Q1 25	—	—
Q2 25	—	—
Q3 25	—	—
Q4 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$59M	-$59M
Q2 22	-$19M	-$21M
Q3 22	-$21M	-$21M
Q4 22	-$22M	-$22M
Q1 23	-$30M	-$30M
Q2 23	-$16M	-$16M
Q3 23	-$18M	-$18M
Q4 23	-$22M	-$22M
Q1 24	-$40M	-$40M
Q2 24	-$42M	-$42M
Q3 24	-$23M	-$23M
Q4 24	-$30M	-$30M
Q1 25	-$31M	-$31M
Q2 25	-$33M	-$33M
Q3 25	-$40M	-$40M
Q4 25	-$28M	-$28M

Capital Expenditures

Quarter	CapEx
Q1 22	$44.0K
Q2 22	$2M
Q3 22	$20.0K
Q4 22	$0
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	-100.0%	+19.4%
Q2 22	-100.0%	-37.5%
Q3 22	-100.0%	-70.4%
Q4 22	-100.0%	-43.8%
Q1 23	—	-1.4%
Q2 23	—	+9.1%
Q3 23	—	+150.5%
Q4 23	—	+16.7%
Q1 24	—	+67.9%
Q2 24	—	+33.2%
Q3 24	—	-8.8%
Q4 24	—	-16.2%
Q1 25	—	-44.1%
Q2 25	—	-11.9%
Q3 25	—	+22.5%
Q4 25	—	+40.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$0	—
Q2 22	$12M	—
Q3 22	$12M	—
Q4 22	$12M	—
Q1 23	$13M	—
Q2 23	$12M	—
Q3 23	$12M	—
Q4 23	$12M	—
Q1 24	$13M	—
Q2 24	$13M	—
Q3 24	$12M	—
Q4 24	$14M	—
Q1 25	$7M	—
Q2 25	$5M	—
Q3 25	$5M	—
Q4 25	$5M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$30M	$13M	—
Q2 22	$20M	$12M	—
Q3 22	$5M	$11M	—
Q4 22	$29M	$12M	—
Q1 23	$30M	$13M	—
Q2 23	$30M	$13M	—
Q3 23	$32M	$13M	—
Q4 23	$35M	$12M	—
Q1 24	$58M	$12M	—
Q2 24	$35M	$12M	—
Q3 24	$26M	$11M	—
Q4 24	$26M	—	$13M
Q1 25	$30M	$9M	—
Q2 25	$32M	$9M	—
Q3 25	$38M	$7M	—
Q4 25	$48M	—	$7M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$706M	$0	$706M
Q2 22	$684M	$0	$684M
Q3 22	$176M	$489M	$665M
Q4 22	$647M	$0	$647M
Q1 23	$183M	$437M	$620M
Q2 23	$214M	$394M	$608M
Q3 23	$138M	$457M	$595M
Q4 23	$144M	$434M	$578M
Q1 24	$161M	$381M	$541M
Q2 24	$243M	$259M	$502M
Q3 24	$98M	$384M	$483M
Q4 24	$65M	$390M	$455M
Q1 25	$119M	$306M	$425M
Q2 25	$88M	$292M	$380M
Q3 25	$77M	$252M	$329M
Q4 25	$96M	$206M	$302M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	83M	-4.5%	-6.6%
Q2 22	83M	+0.1%	-5.5%
Q3 22	83M	+0.0%	+0.5%
Q4 22	83M	+0.0%	-4.4%
Q1 23	83M	+0.1%	+0.2%
Q2 23	83M	+0.1%	+0.2%
Q3 23	83M	+0.0%	+0.2%
Q4 23	83M	+0.0%	+0.2%
Q1 24	84M	+0.6%	+0.7%
Q2 24	84M	+0.4%	+1.0%
Q3 24	84M	+0.2%	+1.2%
Q4 24	84M	+0.0%	+1.2%
Q1 25	85M	+0.8%	+1.5%
Q2 25	84M	-1.7%	-0.6%
Q3 25	79M	-5.6%	-6.4%
Q4 25	78M	-1.2%	-7.5%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	59
Q2 22	$0	59
Q3 22	$0	59
Q4 22	$0	70
Q1 23	$0	70
Q2 23	$0	70
Q3 23	$0	70
Q4 23	$0	75
Q1 24	$0	75
Q2 24	$0	75
Q3 24	$0	75
Q4 24	$0	56
Q1 25	$0	56
Q2 25	$0	56
Q3 25	$0	56
Q4 25	$0	55

Revenue / Employee